STIP1 drives Metabolic Reprogramming in Esophageal Squamous Cell Carcinoma via AHCY-LDHA Axis

Abstract

Glucose metabolism reprogramming has emerged as a hallmark of cancer. We have reported that high temperature food or drink (>65°C) is the key etiological factors contributing to esophageal squamous cell carcinoma (ESCC) progression. Intriguingly, we observed that heat stimulation (42°C) alters glycolytic pathways in esophagus cells, but the underlying mechanisms remain poorly understood. Our findings revealed that stress-induced phosphoprotein 1 (STIP1) exhibits elevated expression in esophageal tissues exposed to heat stimulation (>65°C) compared to unexposed tissues, and its overexpression correlated with clinical grade and predict poor prognosis in ESCC patients. Mechanistically, STIP1 interacts with and activates adenosylhomocysteinase (AHCY; also termed SAHH) and change the conformation of AHCY. STIP1 also facilitates AHCY binding to lactate dehydrogenase A (LDHA), stimulating glycolysis. Notably, AHCY recruits protein arginine methyltransferase 3 (PRMT3) to methylate LDHA at R106, inhibiting ubiquitination-mediated AHCY degradation. In vivo, STIP1 knockout in mice dramatically inhibits 4-nitrochinoline-oxide (4NQO) induced esophageal tumorigenesis. Through virtual screening and functional validation, we identified licochalcone A (LCA) as a potent inhibitor of STIP1-driven ESCC proliferation in vitro and in vivo. In summary, these findings delineate a pro-tumorigenic signaling pathway whereby heat-induced STIP1 upregulation promotes ESCC glycolysis and growth via moonlighting functions that coordinate AHCY activity and LDHA methylation.

Keywords

AHCY / ESCC / glycolysis / heat stimulation / STIP1

References

[1] J. A. Ajani, T. A. D'amico, D. J. Bentrem, et al., “Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology,” Journal of the National Comprehensive Cancer Network: JNCCN17 (2019): 855-883.

[2] H. Sung, J. Ferlay, R. L. Siegel, et al., “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians71 (2021): 209-249.

[3] H. Z. Zhang, G. F. Jin, and H. B. Shen, “Epidemiologic differences in Esophageal Cancer Between Asian and Western populations,” Chinese journal of cancer31 (2012): 281-286.

[4] H. Liang, J. H. Fan, and Y. L. Qiao, “Epidemiology, Etiology, and Prevention of Esophageal Squamous Cell Carcinoma in China,” Cancer Biol Med14 (2017): 33-41.

[5] H. Liu and Z. Dong, “Cancer Etiology and Prevention Principle: “1 + X”,” Cancer Research81 (2021): 5377-5395.

[6] J. Wang, J. Li, D. Cheng, et al., “miR-132-3p Promotes Heat Stimulation-Induced Esophageal Squamous Cell Carcinoma Tumorigenesis by Targeting KCNK2,” Molecular Carcinogenesis62 (2023): 583-597.

[7] K. Bhattacharya and D. Picard, “The Hsp70-Hsp90 go-Between Hop/Stip1/Sti1 is a Proteostatic Switch and May be a Drug Target in Cancer and Neurodegeneration,” Cellular and Molecular Life Sciences78 (2021): 7257-7273.

[8] Y. Xia, J. Chen, G. Liu, et al., “STIP1 Knockdown Suppresses Colorectal Cancer Cell Proliferation, Migration and Invasion by Inhibiting STAT3 Pathway,” Chemico-Biological Interactions341 (2021): 109446.

[9] A. Chao, C. H. Lai, C. L. Tsai, et al., “Tumor Stress-Induced Phosphoprotein1 (STIP1) as a Prognostic Biomarker in Ovarian Cancer,” PLoS ONE8 (2013): e57084.

[10] X. Luo, Y. Liu, S. Ma, et al., “STIP1 is Over-expressed in Hepatocellular Carcinoma and Promotes the Growth and Migration of Cancer Cells,” Gene662 (2018): 110-117.

[11] R. Li, P. Li, J. Wang, and J. Liu, “STIP1 Down-Regulation Inhibits Glycolysis by Suppressing PKM2 and LDHA and Inactivating the Wnt/β-catenin Pathway in Cervical Carcinoma Cells,” Life Sciences258 (2020): 118190.

[12] J. Wang, S. Xie, J. Yang, et al., “The Long Noncoding RNA H19 Promotes Tamoxifen Resistance in Breast Cancer via Autophagy,” Journal of hematology & oncology12 (2019): 81.

[13] J. Wang, K. Ding, Y. Wang, et al., “Wumei Pill Ameliorates AOM/DSS-Induced Colitis-Associated Colon Cancer through Inhibition of Inflammation and Oxidative Stress by Regulating S-Adenosylhomocysteine Hydrolase- (AHCY-) Mediated Hedgehog Signaling in Mice,” Oxid Med Cell Longev2022 (2022): 4061713.

[14] J. Vande Voorde, R. T. Steven, A. K. Najumudeen, et al., “Metabolic Profiling Stratifies Colorectal Cancer and Reveals Adenosylhomocysteinase as a Therapeutic Target,” Nat Metab5 (2023): 1303-1318.

[15] J. Sun, J. Yan, X. Yuan, et al. Cellular & Molecular Biology Letters21 (2016): 21.

[16] Z. Shgn, S. Cen, and Y. Zeng, “Immortalization of human Fetal Esophageal Epithelial Cells Induced by E6 and E7 Genes of human Papilloma Virus 18,” Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi = Zhonghua Shiyan He Linchuang Bingduxue Zazhi = Chinese Journal of Experimental and Clinical Virology13 (1999): 121-123.

[17] T. A. Karakasheva, T. Kijima, M. Shimonosono, et al., “Generation and Characterization of Patient-Derived Head and Neck, Oral, and Esophageal Cancer Organoids,” Curr Protoc Stem Cell Biol53 (2020): e109.

[18] G. Jin, M. Yan, K. Liu, et al., “Discovery of a Novel Dual-Target Inhibitor Against RSK1 and MSK2 to Suppress Growth of Human Colon Cancer,” Oncogene39 (2020): 6733-6746.

[19] C. L. Xiao, X. Z. Chen, Y. L. Du, X. Sun, G. Zhang, and Q. Y. He, “Binomial Probability Distribution Model-Based Protein Identification Algorithm for Tandem Mass Spectrometry Utilizing Peak Intensity Information,” Journal of Proteome Research12 (2013): 328-335.

[20] D. N. Perkins, D. J. Pappin, D. M. Creasy, and J. S. Cottrell, “Probability-based protein identification by searching sequence databases using mass spectrometry data,” Electrophoresis20 (1999): 3551-3567.

[21] R. Roy and H. M. Al-Hashimi, “AlphaFold3 Takes a Step Toward Decoding Molecular Behavior and Biological Computation,” Nature structural & molecular biology31 (2024): 997-1000.

[22] D. Hanahan and R. A. Weinberg, “Hallmarks of Cancer: The Next Generation,” Cell144 (2011): 646-674.

[23] J. Zhu and C. B. Thompson, “Metabolic Regulation of Cell Growth and Proliferation,” Nature Reviews Molecular Cell Biology20 (2019): 436-450.

[24] J. Liu, C. Zhang, T. Zhang, et al., “Metabolic Enzyme LDHA Activates Rac1 GTPase as a Noncanonical Mechanism to Promote Cancer,” Nat Metab4 (2022): 1830-1846.

[25] V. R. Fantin, J. St-Pierre, and P. Leder, “Attenuation of LDH-A expression uncovers a link Between glycolysis, mitochondrial physiology, and tumor maintenance,” Cancer Cell9 (2006): 425-434.

[26] J. Cui, M. Shi, D. Xie, et al., “FOXM1 Promotes the Warburg Effect and Pancreatic Cancer Progression via Transactivation of LDHA Expression,” Clinical Cancer Research20 (2014): 2595-2606.

[27] C. Yeung, A. E. Gibson, S. H. Issaq, et al. Cancer Research79 (2019): 5060-5073.

[28] P. Vizán, L. Di Croce, and S. Aranda, “Functional and Pathological Roles of AHCY,” Frontiers in Cell and Developmental Biology9 (2021): 654344.

[29] Y. Lei, P. Han, Y. Chen, et al., “Protein Arginine Methyltransferase 3 Promotes Glycolysis and Hepatocellular Carcinoma Growth by Enhancing Arginine Methylation of Lactate Dehydrogenase A,” Clinical and translational medicine12 (2022): e686.

[30] A. J. Wolpaw and C. V. Dang, “Exploiting Metabolic Vulnerabilities of Cancer with Precision and Accuracy,” Trends in Cell Biology28 (2018): 201-212.

[31] J. Yang, B. Ren, G. Yang, et al., “The Enhancement of Glycolysis Regulates Pancreatic Cancer Metastasis,” Cellular and Molecular Life Sciences77 (2020): 305-321.

[32] S. Ganapathy-Kanniappan and J. F. Geschwind, “Tumor Glycolysis as a Target for Cancer Therapy: Progress and Prospects,” Molecular cancer12 (2013): 152.

[33] C. Chelakkot, V. S. Chelakkot, Y. Shin, and K. Song, “Modulating Glycolysis to Improve Cancer Therapy,” International Journal of Molecular Sciences (2023): 24.

[34] M. A. Turner, C. S. Yuan, R. T. Borchardt, M. S. Hershfield, G. D. Smith, and P. L. Howell, “Structure Determination of Selenomethionyl S-adenosylhomocysteine Hydrolase Using Data at a Single Wavelength,” Natural Structural Biology5 (1998): 369-376.

[35] I. Barić, K. Fumić, B. Glenn, et al., “S -adenosylhomocysteine Hydrolase Deficiency in a Human: A Genetic Disorder of Methionine Metabolism,” PNAS101 (2004): 4234-4239.

[36] R. Belužić, M. Ćuk, T. Pavkov, et al., “A Single Mutation at Tyr143 of Human S -adenosylhomocysteine Hydrolase Renders the Enzyme Thermosensitive and Affects the Oxidation State of Bound Cofactor Nicotinamide-adenine Dinucleotide,” Biochemical Journal400 (2006): 245-253.

[37] S. J. Park, H. K. Kong, Y. S. Kim, Y. S. Lee, and J. H. Park, “Inhibition of S-adenosylhomocysteine Hydrolase Decreases Cell Mobility and Cell Proliferation through Cell Cycle Arrest,” Am J Cancer Res5 (2015): 2127-2138.

[38] C. M. Greco, M. Cervantes, J. M. Fustin, et al, “S-adenosyl-l-homocysteine Hydrolase Links Methionine Metabolism to the Circadian Clock and Chromatin Remodeling,” Science Advances2020, 6, eabc5629.

[39] H. Girgis, O. Masui, N. M. White, et al., “LDHB May be a Significant Predictor of Poor Prognosis in Osteosarcoma,” Molecular cancer13 (2014): 101.

[40] D. Zhao, S. W. Zou, Y. Liu, et al., “Lysine-5 Acetylation Negatively Regulates Lactate Dehydrogenase A and is Decreased in Pancreatic Cancer,” Cancer Cell23 (2013): 464-476.

[41] L. W. Yuan, X. M. Jiang, Y. L. Xu, et al., “Licochalcone A Inhibits Interferon-Gamma-Induced Programmed Death-Ligand 1 in Lung Cancer Cells,” Phytomedicine80 (2021): 153394.

[42] M. K. Park, J. Ji, K. Haam, et al., “Licochalcone A Inhibits Hypoxia-Inducible Factor-1α Accumulation by Suppressing Mitochondrial Respiration in Hypoxic Cancer Cells,” Biomedicine & Pharmacotherapy133 (2021): 111082.

[43] J. Seo, D. E. Lee, S. M. Kim, E. Kim, and J. K. Kim, “Licochalcone A Exerts Anti-Cancer Activity by Inhibiting STAT3 in SKOV3 Human Ovarian Cancer Cells,” Biomedicines11 (2023): 1264.

RIGHTS & PERMISSIONS

2025 The Author(s). Exploration published by Henan University and John Wiley & Sons Australia, Ltd.